the aid library

LIST OPTIONS

Filter

6844

National Tuberculosis, Leprosy and Lung Disease Orogram Tuberculosis (TB) Isolation Policy

Ministry of Health, Kenya (2018) C1

Apart from implementation of TB infection Prevention and Control measures, treatment of those with active TB of the lungs is key in preventing the spread of the TB bacilli. The Public Health Act CAP 242, section 17 classify TB as notifiable infectious disease and under section 26 as part of preventi... more

Download (516)

View PDF (1038)

WHO consolidated guidelines on drug-resistant tuberculosis treatment
recommended

World Health Organization WHO; Stop TB (2019) C_WHO

The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ... more

Download (351)

View PDF (458)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (748)

View PDF (458)

Guidelines for Pharmacovigilance and Medicine Information System in Rwanda

Ministry of Health, Rwanda (2011) C2

The purpose of these guidelines is to help health workers to participate in the process of continuous surveillance of safety and efficacy of the pharmaceutical products which are used in clinical practice, thus help to achieve the ultimate goal to make safer and more effective treatment available to... more

Download (251)

View PDF (234)

Medicines for HIV, viral hepatitis and sexually transmitted infections in low- and middle- income countries: forecasts of global demand for 2022–2026

World Health Organization WHO (2024) C_WHO

For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries. The purpose of this rep... more

Download (281)

View PDF (305)

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended

World Health Organisation (WHO) (2023) C_WHO

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys... more

Download (1246)

View PDF (900)

Severe Acute Malnutrition Update: Current WHO Guidelines and the WHO Essential Medicine List for Children

Williams, Phoebe CM.; Berkley, James A. (2016) C1

This document was prepared in response to a need to review and potentially update the current recommendations for the antibiotic treatment of both inpatient and outpatient management of severe acute malnutrition (SAM). The current recommendations (Table 1) are based on guidelines published in 2013 i... more

Download (107)

View PDF (114)

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors 2023

World Health Organization WHO (2023) C_WHO

Download (230)

View PDF (241)

Treatment of Leprosy

Lockwod DN. The International Textbook of Leprosy (2018) CC

This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is a key component of leprosy treatment, as it is vital to prevent the progression of the infection. Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with the ... more

Download (629)

View PDF (929)

Pharmacological treatment of mental disorders in primary health care

World Health Organization WHO (2009) CC

The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalised anxiety and sleep disorders; obsessive-compulsive disorders and panic attacks; and alcohol and opioid dependence

Download (586)

View PDF (868)

Surveillance of HIV drug resistance in children newly diagnosed with HIV by early infant diagnosis. Concepte Note

World Health Organization WHO (2017) C_WHO

This concept note describes the methods used to assess the prevalence of any HIVDR and HIVDR by PMTCT exposure among children less than 18 months of age using remnant dried blood spot specimens from early infant diagnosis over a 12-month period

Download (215)

View PDF (236)

Global child and adolescent mental health: The orphan of development assistance for health

Lu C., Li Z.; Patel V. PLOS Medecine (2018) CC

More than 40% of the world population is 24 years old or younger, the vast majority of whom live in low- and lower middle–income countries. Globally, a quarter of disability-adjusted life years (DALYs) for mental disorders and substance abuse is borne by this age group and about 75% of mental diso... more

Download (109)

View PDF (84)

National strategic Plan for the Prevention and Control of Non-Communicable diseases 2020-2025; South Africa National NCD Strategic Plan

World Health Organization WHO (2020) C_WHO

Non-Communicable Diseases (NCDs), including mental disorders, currently pose one of the biggest threats to health and development globally, particularly in low and middle income countries2. It is predicted that unless proven interventions are rapidly implemented in countries, in the short to medium ... more

Download (980)

View PDF (2043)

Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective

World Health Organization (2012) C_WHO

1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization

External Link

Treatment Guidelines for Antimicrobial Use in Common Syndromes

Indian Council of Medical Research - Department of Health Research (2017) C1

The publication of the of the Antimicrobial Treatment Guidelines represents the culmination of the efforts of the Antimicrobial Stewardship Program of ICMR to publish treatment guidelines for common syndromes in India. These guidelines are targeted for the health care settings. It aims to rationali... more

Download (188)

View PDF (217)

Interruption of transmission and elimination of leprosy disease - Technical guidance

World Health Organisation (WHO) (2023) C_WHO

This document provides technical guidance on concepts, definitions, indicators, criteria, milestones and tools to assist leprosy programmes in their journey towards the goals of interruption of transmission and elimination of leprosy disease and through the post-elimination period. Importantly, it p... more

Download (299)

View PDF (313)

CONSENSUS DOCUMENT FOR MANAGEMENT OF SOFT TISSUE SARCOMA AND OSTEOSARCOMA

Indian Council of Medical Research (ICMR) (2016) C1

Prepared as an outcome of ICMR Subcommittee on Soft Tissue Sarcoma and Osteosarcoma | This consensus document on Management of Soft Tissue Sarcoma and Osteosarcoma summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular ... more

Download (275)

View PDF (246)

Plan of Action for Cervical Cancer Prevention and Control 2018-2030

Pan American Health Organization (PAHO) (2018) C_WHO

This Plan envisions a future with the elimination of cervical cancer as a public health problem as a result of universal access to sexual health and STI prevention services, HPV vaccines, effective screening and precancer treatment services, treatment of invasive cervical cancer, and palliative care... more

Download (177)

View PDF (244)

Situation Analysis and Recommendations: Antibiotic Use and Resistance in Kenya

Kenya Medical Research Institute (2011) C2

In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ... more

Download (1018)

View PDF (2032)

Developing intervention strategies to improve community health worker motivation and performance

Frank, Ti.; Kallander, K. Malaria Consortium (2012) C1

This learning paper describes Malaria Consortium’s experience with Integrated Community Case Management (ICCM) in malaria prevention and treatment in Mozambique and Uganda. ICCM is an approach where community-based health workers are trained to identify, treat, and refer complex cases malaria (an... more

WHO consolidated guidelines on drug-resistant tuberculosis treatment recommended

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors recommended

WHO consolidated guidelines on drug-resistant tuberculosis treatment
recommended

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended